Premium
Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
Author(s) -
Kabi Arup K.,
Pal Maynak,
Gujjarappa Raghuram,
Malakar Chandi C.,
Roy Mithun
Publication year - 2023
Publication title -
journal of heterocyclic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.321
H-Index - 59
eISSN - 1943-5193
pISSN - 0022-152X
DOI - 10.1002/jhet.4541
Subject(s) - hydroxychloroquine , pandemic , covid-19 , coronavirus , intensive care medicine , medicine , drug repositioning , drug , severe acute respiratory syndrome coronavirus , public health , virology , pharmacology , pathology , disease , outbreak , infectious disease (medical specialty)
The novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) caused the ongoing pandemic named COVID‐19 which causes a serious emergency on public health hazards of international concern. In the face of a critical medical emergency, repositioning of drugs is one of the most authentic options to design an adequate treatment for infected patients immediately. In this strategy, Remdesivir (Veklury), Hydroxychloroquine appears to be the drug of choice and garnered unprecedented attention as potential therapeutic agents against the pandemic realized worldwide due to SARS‐CoV‐2 infection. These are the breathtaking instances of possible repositioning of drugs, whose pharmacokinetics and optimal dosage are familiar. In this review, we provide an overview of these medications, their synthesis, and the possible mechanism of action against SARS‐CoV‐2.